What is the interpretation of a CBC with differential showing marked thrombocytosis, borderline low hemoglobin, low MCHC, normal white‑cell count, and elevated CRP, and what are the recommended next steps?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Laboratory Interpretation: Thrombocytosis with Borderline Anemia and Inflammation

This patient requires immediate evaluation for a myeloproliferative neoplasm (MPN), specifically essential thrombocythemia (ET), given the marked thrombocytosis (856 × 10³/μL) combined with borderline low hemoglobin and elevated inflammatory markers.

Key Abnormalities Identified

The CBC reveals three critical findings:

  • Marked thrombocytosis: Platelets 856 × 10³/μL (reference: 147-352) - nearly 2.5× upper limit of normal
  • Borderline low hemoglobin: 12.3 g/dL (reference: 12.6-17.0) with low MCHC (31.0 g/dL)
  • Elevated CRP: 31.7 mg/L (reference: 0.0-10.0) indicating significant inflammation
  • Normal ESR: 17 mm (reference: 0-30)

Primary Differential Diagnosis

Essential Thrombocythemia (Most Likely)

The platelet count >450 × 10³/μL meets the threshold for thrombocytosis requiring MPN evaluation 1. The 2007 WHO criteria specify that sustained platelet count ≥450 × 10³/μL warrants investigation for ET 1. This patient's count of 856 × 10³/μL is substantially elevated and cannot be dismissed as reactive.

Reactive Thrombocytosis (Must Exclude)

The elevated CRP (31.7 mg/L) suggests active inflammation, which can cause reactive thrombocytosis 2. However, platelet counts >400 × 10³/μL have 87.8% specificity for distinguishing primary from reactive causes when evaluating for conditions like giant cell arteritis 2. Common reactive causes include:

  • Iron deficiency (suggested by borderline low Hgb and low MCHC)
  • Active infection or inflammation
  • Malignancy
  • Post-surgical state or tissue damage

Immediate Next Steps

1. Confirm Iron Status (Priority #1)

Order serum ferritin, transferrin saturation (TSAT), and iron studies immediately 3. The borderline low hemoglobin (12.3 g/dL) with low MCHC (31.0 g/dL) and normal MCV (85 fL) suggests possible iron deficiency, which is a common cause of reactive thrombocytosis 1.

Interpretation thresholds in the presence of inflammation (CRP 31.7 mg/L):

  • Ferritin <100 μg/L indicates iron deficiency despite inflammation 3
  • TSAT <15% confirms functional iron deficiency 4

2. Repeat CBC in 2-4 Weeks

Confirm persistent thrombocytosis - ET diagnosis requires sustained elevation 1. A single elevated platelet count, especially with concurrent inflammation, may be reactive.

3. Peripheral Blood Smear Review

Request manual review by hematology laboratory 4, 5. Look specifically for:

  • Platelet size and morphology (giant platelets suggest inherited disorders, not ET)
  • Red cell morphology (microcytosis, hypochromia suggest iron deficiency)
  • White cell abnormalities (left shift, immature forms suggest MPN)

The smear is critical to exclude other causes - normal-sized or large platelets support ET, while consistently giant platelets (approaching RBC size) argue against it 5.

4. JAK2 Mutation Testing (If Thrombocytosis Persists)

If platelet count remains >450 × 10³/μL after treating iron deficiency and inflammation, order JAK2 V617F mutation testing 1, 6. This is the first-line molecular test for ET:

  • JAK2 V617F positive in ~60% of ET cases
  • If JAK2 negative, proceed to CALR and MPL mutation testing 6

5. Bone Marrow Biopsy (If MPN Suspected)

Required for definitive ET diagnosis 1. The 2007 WHO criteria mandate bone marrow showing "proliferation mainly of the megakaryocytic lineage with increased numbers of enlarged, mature megakaryocytes" 1.

Clinical Context Assessment

Exclude Reactive Causes

Systematically evaluate for:

  • Infection: The elevated CRP warrants infection workup if clinically indicated
  • Malignancy: Age-appropriate cancer screening, especially if constitutional symptoms present
  • Inflammatory conditions: Rheumatologic disorders, inflammatory bowel disease
  • Recent surgery or trauma: Thrombocytosis can persist 2-3 months post-operatively
  • Medications: Certain drugs can elevate platelets

Assess Thrombotic Risk

If ET is confirmed, calculate the revised International Prognostic Score of Thrombosis for ET (IPSET-thrombosis) 7, 6. Risk stratification determines need for:

  • Low-dose aspirin (81-100 mg daily)
  • Cytoreductive therapy (hydroxyurea first-line)

High-risk features requiring cytoreductive therapy 7:

  • Age >60 years
  • Prior thrombosis
  • Platelet count >1,000 × 10³/μL (this patient is approaching this threshold)
  • JAK2 mutation positive

Evaluate for Symptoms

Specifically ask about 6:

  • Microvascular symptoms: headaches, paresthesias, erythromelalgia (burning pain in extremities)
  • Thrombotic events: DVT, PE, stroke, MI
  • Bleeding complications: paradoxical bleeding with extreme thrombocytosis
  • Splenomegaly symptoms: early satiety, left upper quadrant pain

Management Algorithm

Step 1: Treat iron deficiency if confirmed (ferritin <100 μg/L with inflammation) - oral or IV iron replacement

Step 2: Address underlying inflammation - treat infection/inflammatory condition if identified

Step 3: Repeat CBC in 2-4 weeks after treating reversible causes

Step 4: If platelets remain >450 × 10³/μL, proceed with JAK2 testing and hematology referral

Step 5: If JAK2 positive or clinical suspicion high, bone marrow biopsy for definitive diagnosis

Critical Pitfalls to Avoid

  1. Do not dismiss thrombocytosis as purely reactive without excluding iron deficiency and confirming resolution after treating inflammation
  2. Do not delay JAK2 testing if thrombocytosis persists - early MPN diagnosis affects long-term thrombotic risk management
  3. Do not start aspirin empirically before confirming diagnosis - bleeding risk exists with extreme thrombocytosis
  4. Do not overlook the borderline anemia - this may represent early iron deficiency or bone marrow dysfunction from MPN

Summary Recommendation

Order ferritin, TSAT, and iron studies immediately. Treat iron deficiency if present. Repeat CBC in 2-4 weeks. If thrombocytosis persists (platelets >450 × 10³/μL), order JAK2 V617F mutation testing and refer to hematology for bone marrow biopsy consideration. The combination of marked thrombocytosis with borderline anemia requires systematic exclusion of both reactive causes and essential thrombocythemia 1, 6.

Related Questions

Given a CBC with white blood cell count 3.8 ×10⁹/L, red blood cell count 4.56 ×10⁶/L, hemoglobin 13.9 g/dL, mean corpuscular hemoglobin concentration 32.7 g/dL, absolute monocytes 0.22 ×10⁹/L, and absolute eosinophils 0.07 ×10⁹/L, what is the clinical significance and recommended management?
Should a repeat complete blood count (CBC) be performed for a patient with mild leukocytosis and neutrophilia?
What is the best way to interpret a complete blood count (CBC) report?
What are the causes of a low mean corpuscular hemoglobin concentration (MCHC) with an elevated platelet count (thrombocytosis)?
What does a complete blood count (CBC) showing hemoglobin 11.4 g/dL, hematocrit 33.2 %, mean corpuscular hemoglobin concentration (MCHC) 37 g/dL, platelet count 461 ×10⁹/L, and 1 % myelocytes indicate?
Are there any contraindications or precautions for using Cogentin (benztropine) in a patient with atrial fibrillation?
How long does it take for tic improvement after starting clonidine immediate-release (IR) versus extended-release (ER), and how does the dosage affect the onset of effect?
What is the maximum intramuscular ketamine dose for a 129‑kg combative male patient in the emergency department?
What conditions are associated with chronically mild elevations in hematocrit, hemoglobin, and red blood cell count in a 54-year-old woman?
What travel precautions are recommended for an adult traveling to [CITY], India?
How long does the seizure‑aborting effect of a 5 mg Valtoco (diazepam) nasal spray dose last when administered to each nostril?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.